<DOC>
	<DOCNO>NCT02801669</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety edoxaban patient non-valvular NVAF age 80 year older ineligible available oral anticoagulation therapy .</brief_summary>
	<brief_title>Study DU-176b Aged 80 Years Older</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<criteria>Patients Nonvalvular Atrial Fibrillation ( NVAF ) age 80 year older ineligible available oral anticoagulation therapy Patients active bleeding Patients poorly control hypertension Patients liver dysfunction accompany disorder blood coagulation</criteria>
	<gender>All</gender>
	<minimum_age>80 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>anticoagulant</keyword>
	<keyword>DU-176b</keyword>
	<keyword>edoxaban</keyword>
	<keyword>factor Xa</keyword>
	<keyword>oral</keyword>
	<keyword>prevention</keyword>
	<keyword>atrial fibrillation</keyword>
</DOC>